M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer.
macrophages
tumor biomarkers
tumor microenvironment
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
accepted:
21
07
2020
entrez:
22
8
2020
pubmed:
21
8
2020
medline:
16
9
2021
Statut:
ppublish
Résumé
The immunological microenvironment of primary high-grade serous carcinomas (HGSCs) has a major impact on disease outcome. Conversely, little is known on the microenvironment of metastatic HGSCs and its potential influence on patient survival. Here, we explore the clinical relevance of the immunological configuration of HGSC metastases. RNA sequencing was employed on 24 paired primary tumor microenvironment (P-TME) and metastatic tumor microenvironment (M-TME) chemotherapy-naive HGSC samples. Immunohistochemistry was used to evaluate infiltration by CD8 1468 genes were differentially expressed in the P-TME versus M-TME of HGSCs, the latter displaying signatures of extracellular matrix remodeling and immune infiltration. M-TME infiltration by immune effector cells had little impact on patient survival. Accordingly, M-TME-infiltrating T cells were functionally impaired, but not upon checkpoint activation. Conversely, cytokine signaling in favor of M2-like TAMs activity appeared to underlie inhibited immunity in the M-TME and poor disease outcome. Immunosuppressive M2-like TAM infiltrating metastatic sites limit clinically relevant immune responses against HGSCs.
Sections du résumé
BACKGROUND
The immunological microenvironment of primary high-grade serous carcinomas (HGSCs) has a major impact on disease outcome. Conversely, little is known on the microenvironment of metastatic HGSCs and its potential influence on patient survival. Here, we explore the clinical relevance of the immunological configuration of HGSC metastases.
METHODS
RNA sequencing was employed on 24 paired primary tumor microenvironment (P-TME) and metastatic tumor microenvironment (M-TME) chemotherapy-naive HGSC samples. Immunohistochemistry was used to evaluate infiltration by CD8
RESULTS
1468 genes were differentially expressed in the P-TME versus M-TME of HGSCs, the latter displaying signatures of extracellular matrix remodeling and immune infiltration. M-TME infiltration by immune effector cells had little impact on patient survival. Accordingly, M-TME-infiltrating T cells were functionally impaired, but not upon checkpoint activation. Conversely, cytokine signaling in favor of M2-like TAMs activity appeared to underlie inhibited immunity in the M-TME and poor disease outcome.
CONCLUSIONS
Immunosuppressive M2-like TAM infiltrating metastatic sites limit clinically relevant immune responses against HGSCs.
Identifiants
pubmed: 32819974
pii: jitc-2020-000979
doi: 10.1136/jitc-2020-000979
pmc: PMC7443306
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
Genome Biol. 2015 Mar 31;16:64
pubmed: 25853550
Pharmacol Ther. 2019 Aug;200:55-68
pubmed: 30998941
Arch Gynecol Obstet. 2016 Apr;293(4):695-700
pubmed: 26894303
Nat Rev Clin Oncol. 2020 Aug 5;:
pubmed: 32760014
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
J Immunother Cancer. 2018 Dec 4;6(1):139
pubmed: 30526667
Am J Pathol. 2010 Sep;177(3):1053-64
pubmed: 20651229
Cancer Res. 2000 Oct 15;60(20):5857-61
pubmed: 11059783
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Nat Rev Cancer. 2017 Oct;17(10):605-619
pubmed: 28912577
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
Cancer Res. 2008 Jul 1;68(13):5478-86
pubmed: 18593951
Nat Rev Immunol. 2018 Jan;18(1):19-34
pubmed: 28944771
Cancer Res. 2014 Feb 1;74(3):705-15
pubmed: 24366885
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27
pubmed: 26667886
Nat Rev Drug Discov. 2018 Dec;17(12):887-904
pubmed: 30361552
Cell. 2015 Jan 15;160(1-2):48-61
pubmed: 25594174
Cancer Immunol Res. 2018 Mar;6(3):295-304
pubmed: 29378694
Clin Cancer Res. 2013 Aug 1;19(15):4079-91
pubmed: 23785047
Clin Cancer Res. 2015 Jul 1;21(13):3031-40
pubmed: 25688160
J Immunother Cancer. 2019 Nov 20;7(1):312
pubmed: 31747968
Nat Med. 2011 Oct 30;17(11):1498-503
pubmed: 22037646
Gynecol Oncol. 2012 Feb;124(2):192-8
pubmed: 22040834
J Clin Invest. 2016 Nov 1;126(11):4157-4173
pubmed: 27721235
Cell. 2011 Oct 14;147(2):275-92
pubmed: 22000009
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
Lancet Oncol. 2017 Jul;18(7):849-851
pubmed: 28677562
J Immunol. 2010 Nov 1;185(9):4977-82
pubmed: 20962266
Clin Cancer Res. 2019 Aug 1;25(15):4820-4831
pubmed: 31076549
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
Int Immunol. 2016 Jul;28(7):339-48
pubmed: 27055470
Cancer Immunol Immunother. 2019 Dec;68(12):2067-2080
pubmed: 31720813
Oncoimmunology. 2012 Nov 1;1(8):1323-1343
pubmed: 23243596
Cancer Microenviron. 2013 Aug;6(2):147-57
pubmed: 23104434
Cell Metab. 2019 Jul 2;30(1):36-50
pubmed: 31269428
BMC Cancer. 2012 Jul 23;12:306
pubmed: 22824040
PLoS One. 2009 Jul 29;4(7):e6412
pubmed: 19641607
Sci Transl Med. 2018 Sep 19;10(459):
pubmed: 30232229
PLoS One. 2010 Mar 12;5(3):e9615
pubmed: 20300634
Gynecol Oncol. 2010 Mar;116(3):556-62
pubmed: 20006900
Cancer Res. 2007 Jun 15;67(12):5708-16
pubmed: 17575137
Cancer Sci. 2013 Apr;104(4):437-44
pubmed: 23298232
Clin Cancer Res. 2012 Jun 15;18(12):3281-92
pubmed: 22553348